Rapport Therapeutics (RAPP) Q3 2026 earnings review
Rapport wins bipolar drug trial, while cash burn doubles
Rapport Therapeutics proved its lead brain drug works in a second disorder and used the news to double its cash pile. Chief executive Abraham N. Ceesay reported a mid-stage win in acute bipolar mania and raised $421 million in October and November, lifting cash to $815 million. Meanwhile, third-quarter cash burn more than doubled from a year ago to $42 million as late-stage epilepsy trials ramped up.
| Quarterly operating cash burn | $41.6M up from $17.5M a year ago |
|---|---|
| Cash balance as of November 3 | $815.4M includes $420.7M raised in Oct and Nov |
| Bipolar mania Phase 2 score gap | 3.1 points better than placebo at Week 3 (p=0.045) |
| Cash funding outlook | Extended through end of 2029 (was into second half of 2029) |
⚖️ Verdict: 🟢 Bullish
The story got better because RAP-219 now works in both epilepsy and psychiatric disease, and the fresh financing funds the company through the end of 2029. One caution: the bipolar trial cleared the statistical bar with a p-value of 0.045 because placebo patients improved almost as much as treated patients, and the $421 million raise only extended the funding timeline by a few months because Rapport now has to pay for two additional Phase 3 bipolar trials.
The question now is whether the 3.1-point edge over placebo in bipolar mania is strong enough to hold up across two larger late-stage trials. Either the high placebo response was noise that tighter trial rules can fix, or the drug's true benefit in mania is narrow. The Food and Drug Administration meeting in the first quarter of 2027 will show what trial design regulators require.
🐂 Bull Case
Bipolar Trial Success Opens a Second Market
Rapport is testing RAP-219, a precision pill designed to calm overactive brain regions without causing widespread sedation. Chief executive Abraham N. Ceesay wants the drug to treat both neurological and psychiatric conditions. "RAP-219 now has clinical proof-of-concept in two indications across neurology and psychiatry, giving us the opportunity to serve patients in two multibillion-dollar markets," Ceesay said.
On October 20, the biotechnology company reported that RAP-219 succeeded in a mid-stage trial of 253 adults experiencing acute manic episodes from bipolar disorder. Patients taking the drug for three weeks improved by 15.4 points on the Young Mania Rating Scale, a standard clinical checklist of mania symptoms, beating the placebo group by 3.1 points.
The win matters because it proves the drug works outside epilepsy, where two late-stage trials for focal onset seizures—seizures starting in one area of the brain—are already enrolling patients in the US and China. Side effects remained mild or moderate, and only 3.2% of patients on the drug stopped treatment due to an adverse event.
What to watch: initial data from the long-term safety study in focal onset seizures, due in the fourth quarter of 2026. Clean safety over months of dosing would support the drug's profile across both epilepsy and bipolar disorder.
October Financing Doubles the Cash Balance
Running multiple late-stage brain trials requires hundreds of millions of dollars before a drug developer collects any commercial sales. Rapport ended September with $395 million in cash and short-term investments, down from $436.1 million in June.
Management used the October bipolar trial readout to raise $420.7 million across stocks, pre-funded warrants—paid-up rights to receive shares—and convertible debt due in 2032, plus a small November stock sale. That lifted its cash balance to $815.4 million as of November 3, more than double the third-quarter total by our math, and extended its funding plan "through the end of 2029".
What to watch: the full-year 2026 filing for the conversion price on the new 2032 notes and the exact count of new shares and warrants. Those terms will show how much ownership existing shareholders gave up to secure three years of funding.
🐻 Bear Case
Bipolar Result Clears the Statistical Bar by a Hair
"Our positive Phase 2 results in bipolar mania are transformational for Rapport, accelerating our path to becoming an industry-leading precision neuroscience company," Ceesay said. Earlier this year, the drug developer modified the trial's statistical plan and expanded enrollment so the mid-stage study could potentially count as one of the pivotal trials needed for regulatory approval.
The actual numbers left little room to spare and forced a full late-stage schedule anyway. Rapport said the 15.4-point drop in mania scores was "consistent with the magnitude of improvement reported in recent trials of approved acute mania treatments", but patients on dummy pills improved almost as much.
- Primary endpoint p-value: 0.045, just inside the 0.05 threshold for statistical significance
- Placebo group improvement: 12.3 points, or 80% of the drug group's 15.4-point drop by our math
- Subscale significance: 4 of 11 mania checklist items reached nominal significance over placebo
- Next regulatory step: two full Phase 3 trials planned for the second half of 2027
A p-value of 0.045 means the trial barely cleared the standard cutoff, because the large improvement among placebo patients narrowed the gap to 3.1 points. Instead of using this study to save a late-stage trial, the company now plans to run two full Phase 3 bipolar trials starting in the second half of 2027.
What to watch: the outcome of the Food and Drug Administration meeting in the first quarter of 2027. If regulators require changes to how patients are scored to control placebo responses, the late-stage trials could take longer to enroll.
Four Late-Stage Trials Will Multiply Cash Burn
Rapport is transitioning from a mid-stage developer into a company running multiple large registration programs at once. In the third quarter, research and development spending rose 54% from a year ago to $34.3 million on "operational costs related to clinical development of RAP-219", while cash used in operations more than doubled to $41.6 million.
That spending rate only covers the start of two Phase 3 focal seizure studies and the end of the mid-stage bipolar trial. Over the next year, management plans to start a third Phase 3 epilepsy trial—in generalized tonic-clonic seizures, which affect the whole brain—two Phase 3 bipolar trials, and two early-stage studies, pushing implied cash burn toward $63 million a quarter by our math.
What to watch: research and development spending in the fourth quarter and across 2027 as the new trials launch. Faster cash burn than the $63 million quarterly average would pull the funding cliff back into early 2029, before the new bipolar trials finish.
👓 Other Themes
FDA Clears Pain Drug for Human Testing
Until now, Rapport's clinical pipeline rested entirely on a single molecule, RAP-219. This quarter the US regulator cleared an Investigational New Drug application—permission to begin human testing—for a second compound, RAP-641, which targets a specific nerve receptor for chronic pain and migraine. The neurology group paused an earlier pain study of RAP-219 last December to prioritize this drug, and expects initial Phase 1 data in the second half of 2027.
💲 Other KPIs
Share count rose 25.9% from a year ago, driven by the September 2025 stock offering of 11.1 million shares. Because the October 2026 stock and warrant sales closed after the third quarter ended, the diluted share count will jump again in the fourth quarter.
Overhead and administrative spending grew 26.8% from a year ago and 4.0% from last quarter as the company hired more staff and paid higher compensation. Year-over-year growth slowed from 52.6% in the first quarter and 37.8% in the second quarter.
Cash interest earned on bank balances and short-term investments rose 25.8% from a year ago, when the September 2025 financing closed late in the period. It fell from $4.2 million last quarter as the cash balance declined before the October capital raise.
🔮 Guidance
Raised. Management expects its $395 million third-quarter cash balance plus $420.7 million from the October and November financings to fund operations through the end of 2029, up from its prior plan of into the second half of 2029. By our math, that leaves about $62.7 million per quarter over the next 13 quarters, showing the two new Phase 3 bipolar trials will consume most of the fresh $420.7 million.
New. Following the October mid-stage readout, the biotechnology group plans to meet with the US regulator in the first quarter of 2027 and start two pivotal Phase 3 trials in the second half of 2027.
New. After receiving regulatory clearance to begin human testing of RAP-641 for chronic pain and migraine, the company plans to start a Phase 1 trial and report initial data in the second half of 2027.
Unchanged. Rapport narrowed the timeline for initial pharmacokinetic data—measurements of how long the drug stays in the bloodstream—for its long-acting injectable version of RAP-219 from 2027 to the third quarter of 2027.
Unchanged. The drug developer still expects to report initial data from the long-term safety extension study in focal onset seizures during the fourth quarter of 2026.
Unchanged. Preparations remain on track to start a late-stage trial of RAP-219 for primary generalized tonic-clonic seizures in the first half of 2027.
❓ Key Questions
Why didn't the bipolar trial qualify as confirmatory?
Earlier in 2026, Rapport expanded the Phase 2 bipolar mania trial and updated its statistical plan so it could potentially serve as confirmatory evidence. Why does the new plan still require two full Phase 3 trials?
How many shares and warrants were issued in October?
The company raised $420.7 million in October and November across stock, pre-funded warrants, and convertible notes due in 2032, but did not disclose the split between debt and equity or the conversion price.
What drove the 12.3-point placebo drop in bipolar mania?
Patients on placebo improved by 12.3 points on the Young Mania Rating Scale, equal to 80% of the drug group's improvement by our math. How will management change trial site selection or scoring in Phase 3 to contain placebo responses?
When will the Phase 3 focal seizure trials finish enrolling?
The FOCUS 1 and FOCUS 2 trials are enrolling patients in the US and China, but Rapport has not provided an expected readout year or target enrollment completion date.